文献速递乳腺癌支持与姑息治疗

异构体α特异性PI3K抑制剂的毒性管理

Management of toxicity to isoform α-specific PI3K inhibitors.
PubMed 文献 · Ann Oncol · 2019-01-01

本文综述了PI3K/AKT通路抑制剂(尤其是异构体α特异性PI3K抑制剂)在肿瘤治疗中的毒性管理。该类药物的副作用常见但可逆,包括高血糖、皮疹、口腔炎、腹泻、恶心和疲劳,常导致剂量减少、治疗延迟或停药,影响生活质量和疗效。早期识别、主动干预、预防策略及跨学科管理是关键。

要点

  • PI3K/AKT通路抑制剂毒性常见但可逆,包括高血糖、皮疹、口腔炎、腹泻等。
  • 毒性可致剂量调整或停药,影响疗效,需早期识别和主动干预。
  • 跨学科管理应包括患者教育、频繁监测、预防策略及早期干预。

核心结论

  • PI3K/AKT通路抑制剂的毒性常见但可逆,早期识别和主动管理可减少治疗中断,保障疗效和生活质量。

研究设计与样本

  • 本文为综述,检索范围未在摘要中明确说明,主要总结异构体α特异性PI3K抑制剂的毒性管理策略。

主要发现

  • PI3K/AKT通路改变在癌症中常见,尤其在乳腺癌中约70%的肿瘤存在可能导致通路过度激活的遗传改变。
  • PI3K/AKT通路抑制剂的毒性包括高血糖、皮疹、口腔炎、腹泻、恶心和疲劳,常导致剂量减少、治疗延迟和停药。
  • 大多数副作用在药物中断后可逆,因药物半衰期短,早期干预可管理。

临床怎么用

  • 对接受PI3K通路抑制剂的患者应进行跨学科主动管理,包括全面教育、频繁监测、早期毒性识别、积极干预和预防策略。

局限性

  • 本文为综述,未报告具体研究设计、样本量或检索策略,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alterations in the phosphoinositide 3-kinase (PI3K)/AKT pathway are frequently found in cancer and are especially common in breast cancer, where it is estimated that 70% of tumors have some type of genetic alteration that could lead to pathway hyperactivation. A variety of PI3K pathway inhibitors have been developed in an attempt to target this pathway and improve cancer control. One of the challenges in treating patients with PI3K/AKT pathway inhibitors is the associated toxicity from on-target and off-target effects. Such side-effects are common, but reversible, and include hyperglycemia, rash, stomatitis, diarrhea, nausea, and fatigue. As a result, dose reductions, treatment delays, and treatment discontinuation are frequently reported. This impairs not only patients' quality of life but also treatment efficacy. Most side-effects are reversible with drug interruption, since these drugs typically have a short half-life and are manageable with early intervention. An interdisciplinary approach with proactive management of patients receiving PI3K pathway inhibitors should include comprehensive education of patients about the range of toxicities, frequent monitoring, early toxicity recognition, active intervention, as well as prophylactic strategies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Nunnery SE, Mayer IA. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019. PMID: 31928691. doi:10.1093/annonc/mdz440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。